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Abstract
Objective: one focus in the medical care of HIv-in-
fected patients today is cardiovascular risk reduction.
Metabolic  disturbances  occur  frequently  in  patients
taking protease inhibitors (PI) and are a major risk fac-
tor  for  atherosclerosis.  with  few  published  head-to-
head studies substance-specific differences concerning
metabolic effects are insufficiently defined. therefore
this cohort study directly compared the metabolic pro-
files  of  boosted  atazanavir  (atv/r),  fosamprenavir
(fPv/r) and saquinavir (sQv/r).
Methods: data from a cohort of 124 HIv patients ini-
tiating a boosted regimen with one of the PIs at the
University of Munich (LMU) infectious diseases out-
patient clinic were retrospectively analyzed. the main
outcome measures were median absolute total choles-
terol levels and median relative change of total choles-
terol levels after six months of PI-therapy. a multi-
variate  linear  regression  model  was  built  to  identify
and control for potential confounders of the associa-
tion between PI-therapy and serum cholesterol level.
Results: 84 patients were treated with atv/r, 23 pa-
tients received fPv/r and 17 patients sQv/r. demo-
graphically  the  cohort  constituted  a  representative
sample of HIv-infected patients in germany. there
were no statistically significant differences between the
comparison groups at baseline.
after six months of therapy median serum choles-
terol in the atv/r group dropped significantly from
204  mg/dl  to  186  mg/dl,  while  in  the  fPv/r  and
sQv/r groups a rise in serum cholesterol levels was
observed from 179 mg/dl to 204 mg/dl and from 173
mg/dl to 209 mg/dl respectively. the multivariate lin-
ear regression model identified a significant interaction
between bMI at baseline and treatment with fPv/r:
patients with higher bMI showed more prominent in-
creases in serum cholesterol while taking fPv/r com-
pared to patients with lower bMI.
Conclusion: this cohort study demonstrated the most
favourable  impact  on  serum  cholesterol  levels  and
thus  cardiovascular  risk  for  atv/r  compared  to
fPv/r  and  sQv/r  under  real-life  conditions.  given
the statistical interaction detected between fPv/r and
bMI  further  studies  assessing  metabolic  profiles  of
different antiretroviral drugs in specific patient popu-
lations are urgently needed.
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erides, glucose, metabolism, body mass index, dyslipi-
demia, obesity, cardiovascular risk, multivariate linear
regression, statistical interaction
Abbreviations:
atv/r boosted atazanavir 
bMI body mass index
caRt combination antiretroviral therapy
fPv/r boosted fosamprenavir
LPv/r boosted lopinavir
PI protease inhibitor
PLHa  people living with HIv/aIds
Rtv ritonavir
sQv/r boosted saquinavir
IntRodUCtIon and obJECtIvEs
Metabolic and cardiovascular health issues are becom-
ing an increasing problem in germany and other in-
dustrialized  countries.  Cardiovascular  complications
[1-8] now are among the leading causes of mortality in
these countries [9-12].
since the introduction of combination antiretrovi-
ral therapy (caRt) mortality due to aIds-defining ill-
nesses has considerably decreased among people living
with HIv/aIds (PLHa), resulting in an increase of
life expectancy to almost that of the general popula-
tion  [13,  14].  therefore  non-HIv-related  causes  of
death,  among  them  cardiovascular  diseases,  are  be-
coming more relevant among PLHa [14-17]. In addi-
tion, both HIv-infection itself [18-21] and various an-
tiretroviral  drugs  are  also  associated  with  increased
cardiovascular risk [22-24]. Elevated serum cholesterol
has been shown to be a major cause for atherosclero-
sis in numerous studies [3-5, 8] and this association
has also been confirmed in PLHa [25].
with a broad spectrum of antiretroviral drugs avail-
able, the focus of HIv therapy today lies on managing
the patients’ overall health situation, including meta-
bolic and cardiovascular as well as quality of life issues
[26]. Choosing antiretroviral drugs with a favourable
metabolic profile is the primary specific intervention
recommended to minimize the cardiovascular risk bur-
den in HIv-patients even before identification of oth-
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9) Gyalrong_Umbruchvorlage  14.02.11  14:32  Seite 85er modifiable cardiovascular risk factors potentially re-
quiring drug therapy [27].
Protease  inhibitors  (PIs)  are  an  essential  part  of
modern caRt and recommended as part of first-line
HIv-therapy in different guidelines [28-31]. However,
unfavourable metabolic effects like elevation of serum
lipids, impaired glucose tolerance, and increased risk
of myocardial infarction have mainly been associated
with this drug class [22, 24, 25, 32-37]. the metabolic
effects, especially the impact on serum lipids, is a class
effect  of  PIs,  however  there  seem  to  be  substance-
specific differences [24]. thus, knowledge of the dif-
ferent metabolic profiles of the various PIs offers the
possibility  to  optimize  caRt  efficacy  while  keeping
cardiovascular risk as low as possible. several newer
PIs show fewer metabolic side effects than have been
observed  for  ritonavir-boosted  lopinavir  (LPv/r)  or
ritonavir (Rtv) in therapeutic dosage [24, 32-35, 38-
41]. Especially atazanavir (atv) so far has shown a
relatively  favourable  lipid  profile  [42-45].  saquinavir
(sQv) as well has been observed to have few negative
effects  on  the  serum  lipids  [46-49].  data  about  the
metabolic properties of fosamprenavir (fPv) are con-
flicting [50-52].
Currently available data do not allow for a conclud-
ing assessment of the differences of the various PIs’
effect on lipid and glucose metabolism and cardiovas-
cular risk. Moreover, to date little is known about the
various interactions of the PIs‘ metabolic effects with
other patient characteristics such as body mass index
(bMI), blood pressure, or smoking habits, which influ-
ence a patient’s metabolic situation as well.
the aims of the present study were to directly com-
pare  the  three  PIs  atv,  fPv  and  sQv,  for  which
favourable metabolic profiles have been observed in
different  studies,  with  regard  to  their  influence  on
metabolic parameters affecting cardiovascular risk as
well as assessing possible interactions of the PIs with
patient characteristics like bMI and blood pressure.
MEtHods and statIstICs
this study took place at the Ludwig-Maximilians-Uni-
versity of Munich infectious diseases outpatient clinic.
the University of Munich ethics committee approved
the study. all HIv-infected patients seen between Jan-
uary 1, 2000 and March 31, 2008 were screened for
their eligibility. all adult patients initiating therapy with
atv 300 mg qd, fPv 700 mg bid, or sQv 1000 mg
bid  within  a  Rtv-boosted  caRt-regimen  (atv/r,
fPv/r or sQv/r) for whom a follow-up of at least six
months was available were included into the analysis.
double-PI therapy and changes of the caRt regimen
as  well  as  initiation  or  changes  of  a  lipid-lowering
medication during the first six months of PI-therapy
were not allowed.
Patients were usually seen at the clinic every three
months.  at  these  visits  serum  levels  of  cholesterol,
triglycerides,  and  glucose,  Cd4  cell  count  and  viral
load,  as  well  as  blood  pressure,  weight,  and  current
medication  were  routinely  documented.  all  demo-
graphic, HIv-related, and metabolic data were extract-
ed from patient files and the outpatient clinic database.
Cardiovascular risk was calculated for each patient
at baseline and after 6 months of PI therapy using the
Heartscore-tool  developed  by  the  European  society
of Cardiology in the version specific for germany [2,
3, 53]. the score value is calculated on the basis of
age, gender, smoking behaviour, systolic blood pres-
sure and serum cholesterol level and describes the risk
of  a  fatal  cardiovascular  event  within  the  next  10
years. according to European Joint task force guide-
lines a patient is considered at high cardiovascular risk
if the score is above 5% [3, 54].
this study was carried out as a retrospectively ana-
lyzed cohort study, the main outcome measures were
median  absolute  total  cholesterol  levels  and  median
relative  change  of  total  cholesterol  levels  after  6
months of PI-therapy.
to  identify  potential  confounding  variables  influ-
encing the association between PI-therapy and serum
cholesterol level a multivariate linear regression model
was designed. the outcome variable was serum cho-
lesterol level after 6 months of therapy with one of
the  PIs,  main  predictor  variables  were  PI  used  and
baseline cholesterol. Collinearity was ruled out by as-
sessing  variance  inflation.  Potential  confounding  co-
variates known from the literature were assessed, vari-
ables shown to be confounders were included in the
final  model.  all  parameters  in  the  final  model  were
tested for two-way interaction.
all  statistical  analyses  were  performed  using
sPss™  software,  version  15.0  (sPss,  Munich,  ger-
many). for comparison of the cohorts Kruskal-wallis-
H-test and Chi2-test were used, as applicable. Intra-
group  analyses  of  the  changes  of  parameters  over
time were performed using the wilcoxon-test for met-
ric  variables  and  the  Mcnemar-test  for  categorical
variables.
REsULts
PatIEnts and basELInE CHaRaCtERIstICs
during  the  study  period  444  patients  starting  a  PI-
containing regimen were seen at the outpatient clinic,
124 patients met eligibility criteria for inclusion into
the analysis. of these, 84 patients (68%) initiated ther-
apy with atv/r, 23 patients (19%) initiated therapy
with fPv/r, and 17 patients (14%) with sQv/r. the
remaining patients were excluded because they were
treated with a different PI (199 patients), received a
double-PI-regimen or an unusual dosage of the PI (87
patients),  or  insufficient  follow-up  was  available  (34
patients). additional follow up documentation of 24
months after starting PI-therapy was available for 86
patients. the baseline demographic and clinical char-
acteristics of the patients are shown in table 1. there
were no significant differences with regard to demo-
graphic characteristics, HIv disease characteristics, an-
tiretroviral therapy, or cardiovascular risk factors be-
tween the 3 groups receiving different PI-based caRt
at baseline.
MEtaboLIC PRofILE and CaRdIovasCULaR RIsK
the changes of different metabolic parameters exam-
ined during the first 6 months after initiating therapy
with one of the PIs are shown in table 2.
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an serum cholesterol level was highest at 204 mg/dl in
the atv/r-group. In the fPv/r- and sQv/r-groups
the median values were 179 mg/dl and 173 mg/dl, re-
spectively. the differences between the groups were
not statistically significant (p= 0.19; inter-group com-
parison).  after  six  months  of  therapy  the  median
serum cholesterol level significantly decreased to 186
mg/dl in the patients taking atv/r (p= 0.009; intra-
group  comparison).  the  median  value  rose  to  204
mg/dl in the patients taking fPv/r (p= 0.03; intra-
group comparison), and to 209 mg/dl in the patients
taking sQv/r (p= 0.15; intra-group comparison). at
month 6 of therapy there was a trend towards a lower
median  serum  cholesterol  in  patients  taking  atv/r
(p= 0.055; inter-group comparison) (fig. 1). Regarding
the relative change of the serum cholesterol levels at
month 6 compared to baseline values, a significant dif-
ference between the PI groups was seen (p=0.0002;
inter-group comparison): In the atv/r-group serum
cholesterol had decreased by -6%, in contrast to both
the fPv/r- and sQv/r-group, in which a respective
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Table 1. baseline demographic and clinical characteristics of patients starting a new PI-based caRt regimen.
Starting therapy with ATV/r FPV/r SQV/r pa
Characteristic
Number of patients n 84 23 17
DEMOGRAPHIC CHARACTERISTICS
Male patients n (%) 62 (74) 18 (78) 14 (82) 0.72
Age (years) Median  43 44 41
(IQRb) (37; 54) (38; 50) (35; 50) 0.69
Caucasian patients n (%) 66 (79) 21 (91) 14 (82) 0.71
HIV risk category MSMc n (%) 41 (49) 14 (61) 12 (70)
heterosexual n (%) 17 (20) 4 (17) 2 (12) 0.76
other n (%) 26 (31) 5 (22) 3 (18)
HIV DISEASE CHARACTERISTICS
Duration of known HIV infection (years) Median 8.8 10.5 8.8
(IQR) (5.4; 12.8) (6.3; 15.3) (4.7; 10.5) 0.41
Previous AIDS n (%) 34 (40) 8 (35) 9 (53) 0.53
CD4 cell count (cells/ﾵl blood) Median 343 320 262
(IQR) (221; 496) (138; 595) (81; 551) 0.59
Patients with undetectable viral loadd n (%) 37 (44) 8 (35) 6 (35) 0.73
ANTIRETROVIRAL THERAPY
Previous cART exposure n (%) 79 (94) 20 (87) 16 (94) 0.50
Previous PI exposure n (%) 55 (66) 15 (65) 14 (82) 0.40
Cumulative cART exposure (years) Median 6,9 7,3 5,2
(IQR) (3.2; 8.7) (3.8; 9.6) (3.5; 8.7) 0.30
previous cART no cART n (%) 15 (18) 8 (35) 1 (6) 0.35
other PI n (%) 40 (48) 11 (48) 10 (59) 0.69
NRTI and/or 
NNRTI only n (%) 29 (35) 4 (17) 6 (35) 0.12
CARDIOVASCULAR RISK FACTORS
BMI Median 23,7 23,6 21,5
(IQR) (21.3; 25.4) (20.5; 25.1) (19.3; 23.2) 0.50
Current smoker n (%) 39 (46) 9 (39) 6 (35) 0.23
Arterial hypertensione n (%) 35 (42) 11 (48) 6 (35) 0.73
Diabetes mellitus n (%) 7 (8) 1 (4) 0 (0) 0.40
Current lipid-lowering therapy n (%) 5 (6) 2 (9) 2 (12) 0.67
a: Kruskal-wallis-H-test for metric variables, Chi2-test for categorical variables; p-value for inter-group comparisons
b: inter quartile range
c: Men having sex with men
d: less than 50 copies per ml of plasma
e: diastolic blood pressure ≥90mmHg and/or systolic blood pressure ≥140mmHg or antihypertensive medication
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and  fPv/r)  and  +6%  (p=  0.016;  comparison  of
atv/r and sQv/r) was observed. no significant dif-
ference  could  be  found  between  the  patients  taking
fPv/r and those taking sQv/r (p= 0.28; comparison
of fPv/r and sQv/r) (table 2).
In the further course between 6 and 24 months af-
ter initiating PI therapy cholesterol levels in patients
on atv/r were continuously lower than in the other
groups. In the atv/r-group the median serum cho-
lesterol at month 24 was 198 mg/dl, in the fPv/r-
and sQv/r-group the values were 228 mg/dl and 214
mg/dl, respectively.
the median serum triglyceride level at baseline in
the fPv/r-group was at 136 mg/dl and thus in the
favourable range below 150 mg/dl [3, 4, 55, 56]. In the
patients starting therapy with atv/r and sQv/r the
median baseline values for the triglycerides were 187
mg/dl and 205 mg/dl, respectively. after the first 6
months of PI therapy the median value in the atv/r-
collective remained basically unchanged at 187 mg/dl
whereas an increase to 169 mg/dl in the fPv/r group
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Table 2. Changes in the metabolic and cardiovascular profile during PI-therapy.
PI group ATV/r FPV/r SQV/r p-valuea
Characteristic
Number of patients 84 23 17
Serum cholesterol
at baseline [mg/dl] Median 204 179 173
(IQR) (159; 251) (148; 217) (143; 221) 0.19
at month 6 [mg/dl] Median 186 204 209
(IQR) (157; 228) (177; 284) (164; 278) 0.055
relative change at month 6 % (Median) -6 +21 +8 0.0002
Serum triglycerides
at baseline  [mg/dl] Median 187 136 205
(IQR) (113; 334) (87; 289) (143; 366) 0.20
at month 6  [mg/dl] Median 186 169 218
(IQR) (119; 280) (122; 239) (120; 342) 0.90
Serum glucose
at baseline [mg/dl] Median 90 87 89
(IQR) (82; 101) (83; 97) (78; 99) 0.70
at month 6 [mg/dl] Median 91 90 97
(IQR) (83; 101) (83; 103) (89; 118) 0.17
High cardiovascular riskb
at baseline n (%) 23 (27) 2 (9) 2 (12) 0.088
at month 6 n (%) 20 (24) 3 (13) 3 (18) 0.50
a: Kruskal-wallis-H-test for metric variables; p-value for inter-group comparisons
b: risk of developing a fatal cardiovascular event over the next ten years >5%, according to the Heartscore [2, 3, 53] 
Fig. 1. Change of serum choles-
terol levels in the course of the
therapy. 
In the boxplot, the central line
represents the median, the box
denotes the inter quartile range,
the whiskers encompass the 1,5-
fold inter quartile range, outliers
are not indicated
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were observed. However, neither the inter-group dif-
ferences nor the changes over time within the differ-
ent PI groups were statistically significant (table 2).
Median serum glucose values showed no significant
variation between the comparison groups and no rele-
vant changes over the time course of the therapy with
the  PIs.  the  majority  of  the  patients  in  all  three
groups had normal fasting serum glucose levels below
110 mg/dl throughout the study period (table 2).
at  baseline  the  proportion  of  patients  with  high
cardiovascular risk, i.e., a Heartscore-risk of >5% [2,
3, 54], was highest at 27% in the group starting thera-
py  with  atv/r.  In  the  fPv/r-group  and  sQv/r-
group the prevalence was 9% and 12%, respectively.
after 6 months of PI therapy the proportion of high-
risk patients was slightly lower in the atv/r-group at
24%. In the other groups a trend towards a rise to
13% and 18% could be observed in the patients taking
fPv/r and sQv/r, respectively (table 2).
there  were  no  statistically  significant  differences
between the PIs regarding their efficacy in suppressing
HIv. Less than half of the patients in all PI-groups
had  a  non-detectable  viral  load  at  baseline.  after  6
months of therapy the proportion had risen to >70%.
the median Cd4-cell count was between 262 and 343
cells/ﾵl at baseline and rose to values between 292 and
400 cells/ﾵl after 6 months of therapy.
MULtIvaRIatE LInEaR REgREssIon
among the covariates tested only bMI at baseline was
identified as confounding the association between PI
group (atv/r vs. sQv/r vs. fPv/r) and cholesterol
level at month 6 and therefore was included in the fi-
nal model. In addition, significant interaction between
treatment with fPv/r and bMI at baseline was detect-
ed (table 3).
the effect of this interaction can be illustrated by
dichotomizing  bMI  at  the  median  value  of  23.5
kg/m2 (table 4). while for patients with higher bMI
values the use of fPv/r was associated with the high-
est cholesterol levels after 6 months, for patients with
lower bMI predicted serum cholesterol in the fPv/r
group was identical to those in the sQv/r group (all
compared to therapy with atv/r).
dIsCUssIon
In this cohort study comparing the effect of caRt ei-
ther containing atv/r, sQv/r, or fPv/r on serum
cholesterol  levels  after  6  months  of  therapy  under
real-life conditions we demonstrated the lowest serum
cholesterol levels in the atv/r treated patients. this
is even more remarkable considering that at baseline
the median serum cholesterol level was highest in the
atv/r group. during the first 6 months of therapy
the median serum cholesterol significantly decreased
by 18 mg/dl in the atv/r-group (p=0.009), whereas
in the fPv/r and sQv/r-groups an increase in medi-
an cholesterol was observed. thus, in contrast to base-
line the serum cholesterol profile at month 6 was most
favourable in the patients taking atv/r. the observed
differences of >20 mg/dl in median serum cholesterol
between the groups appear clinically relevant, especial-
ly in patients at a high cardiovascular risk, even though
predefined statistical significance was missed for the
bivariate inter-group comparison (p=0.055), likely due
to the differences in baseline median cholesterol val-
ues between the PI groups. when adjusting for differ-
ent baseline levels by comparing the median relative
changes in serum cholesterol during the first 6 months
of  therapy  the  difference  between  the  PI-groups  is
significant (p=0.0002) and strongly in favour of thera-
py  with  atv/r.  therefore  our  study  confirms  the
favourable influence of atv/r on serum cholesterol
described in current literature [42-45, 52, 57-60].
for sQv/r several trials have indicated a compara-
tively  beneficial  influence  on  serum  cholesterol  [24,
39, 46, 47], an effect not replicated in our study where
treatment with sQv/r was associated with a modest
increase in serum cholesterol.
In  contrast  to  the  alert-study  [52],  our  findings
confirm the rather disadvantageous effect of fPv/r
on serum cholesterol [27] found in several other stud-
ies [50, 51, 61]. However, considering the interaction
identified in the multivariate linear regression model,
this unfavourable effect of fPv/r on serum choles-
terol may not be universal but seems to mainly affect
patients with a higher bMI. this suggests that while it
might  be  prudent  to  avoid  therapy  with  fPv/r  in
obese patients, fPv/r may be a relatively safe treat-
ment option in patients with normal weight.
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Table 3. Multivariate linear regression model for serum cho-
lesterol levels after 6 months of PI-therapy.
Parameter Coefficient p-value R2a
intercept 59.9 0.071
Therapy using ATV/r reference
Therapy using SQV/r 34.5 0.007
Therapy using FPV/r -83.8 0.15
fPV/rￗBMI at baseline 5.6 0.021
BMI at baseline 1.5 0.26
Serum cholesterol at baseline 0.5 < 0.001
0.49
a: Coefficient of determination of the regression model
Table 4. Influence of bMI stratum on the effect of fPv/r on
the serum cholesterol level after 6 months of PI therapy.
Parameter Coefficient p-value
ATV/r reference
SQV/r 36.6 0.004
FPV/r
for BMI >23.5 kg/m2 58.1 <0.001
for BMI ≤23.5 kg/m2 36.6 0.023
Serum cholesterol at baseline 0.5 <0.001
BMI of >23.5 kg/m2 at baseline 15.0 0.13
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tablished cardiovascular risk factors [3-5, 8], calculated
cardiovascular  risk  within  the  first  6  months  of  PI
therapy parallelled the changes in cholesterol values: in
the group taking atv/r the proportion of patients
with high cardiovascular risk decreased, whereas in the
patients using fPv/r and sQv/r the proportion with
high cardiovascular risk increased. 
the  HeartsCoRE  used  here  for  determining  the
patients’ cardiovascular risk has not been validated in
HIv-infected populations so far. However, its advan-
tage over other available cardiovascular risk calculators
is its validation specifically in European populations.
furthermore,  based  on  parameters  readily  available
through measurements in clinical routine, it describes
the risk of a fatal cardiovascular event rather than oth-
er, less clearly defined endpoints [2].
It is well known that atherosclerosis is most strong-
ly associated with levels of LdL-cholesterol [4, 26],
which  were  not  available  for  many  patients  in  this
study. However, there is a robust correlation between
LdL-cholesterol  and  total  serum  cholesterol,  there-
fore the latter can well serve as a surrogate variable for
determining a patient’s cardiovascular risk profile [4].
another  limitation  of  the  study  is  the  relatively
small sample size and the unbalanced distribution of
patients  between  the  comparison  groups,  potentially
leading to an impairment of statistical significance of
some of the analyses. However, the group of patients
examined  here  can  be  regarded  as  a  representative
sample of HIv-infected individuals in germany based
on  their  demographic  characteristics  [62].  further-
more, different univariate and multivariate approaches
to analyze the effect of the examined PIs on serum
cholesterol  yielded  consistent  results,  demonstrating
the robustness of the statistical analyses. an immanent
limitation of a non-interventional, retrospectively ana-
lyzed study is the potential problem of missing data
and incomplete data standardization. this was mini-
mized by the use of different data sources including
chart documentation of regular clinic visits scheduled
every three months and a standardized patient data-
base established at the clinic since 1997. In addition, a
main strength of this study is the analysis of data de-
rived from a real-life patient population. In this way
clinical reality can be better represented than by the
highly selected patient populations used for interven-
tional studies. 
In conclusion, in a real-life patient population we
confirmed  that  treatment  of  HIv  infection  with  a
atv/r based regimen had a more favourable impact
on serum cholesterol levels and therefore cardiovascu-
lar risk compared to sQv/r or fPv/r based regimens.
fPv/r  was  associated  with  the  highest  increase  in
serum cholesterol, specifically in overweight patients,
whereas its effects on cholesterol may be comparable
to sQv/r in patients with a bMI ≤23,5 kg/m2. In the
light of growing interest in personalized medicine [63]
and  with  obesity  and  cardiovascular  disease  getting
ever more prevalent [4, 64-68] this may be an example
of how to better tailor caRt regimens considering a
patient’s metabolic and cardiovascular profile.
based  on  these  results  more  and  larger  studies
should be undertaken to specifically address the multi-
ple interdependencies between effects of caRt and
patient characteristics affecting cardiovascular risk.
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